Wednesday, December 1, 2010

Targacept (NASDAQ:TRGT) Valuation Low Says Needham

Saying they believe the valuation on Targacept (NASDAQ:TRGT) is too low, Needham & Company maintains their "Buy" rating on the company.

"Targacept is scheduled to hold an investor R&D day tomorrow (Thursday) in NYC. Valuation is low in our opinion (EV $340MM), given the strength of the TC-5214 program in depression and the depth of the NNR pipeline in cognition and inflammatory disease...We continue to believe the depression market is attractive for add-on agents," said Needham.

Targacept closed Wednesday's trading session at $21.84, increasing by $0.64, or 3.02 percent. Needham as a price target on them of $32.

No comments: